Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

US FDA issues warning letters to retailers against underage sale of ZYN nicotine pouches

Published 04/04/2024, 06:03 PM
Updated 04/04/2024, 09:01 PM
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

(Reuters) - The U.S. Food and Drug Administration on Thursday said it had issued warning letters and filed civil money penalty complaints against retailers engaged in underage sale of various flavors of ZYN nicotine pouches.

The FDA said it had issued 119 warning letters to brick-and-mortar retailers and had filed 41 civil money penalty complaints seeking more than $55,000 in total for underage sales of flavored ZYN nicotine pouches, including espressino, black cherry, lemon spritz, and cucumber lime.

ZYN nicotine pouches are manufactured by Swedish Match, which is owned by Marlboro maker Philip Morris International (NYSE:PM). PMI claims that the pouches do not contain tobacco and are inherently smoke-free.

PMI did not immediately respond for a request for comment.

The FDA said it was illegal for any retailer to sell any tobacco product - including cigarettes, e-cigarettes, cigars, and nicotine pouches — to anyone under the age of 21. The agency added that nicotine pouches were a type of tobacco product.

"There is no excuse for selling tobacco products to any underage person, and FDA will hold retailers accountable for those violations—especially those who continue to do so after being warned," said Brian King, director of the FDA's Center for Tobacco Products.

New tobacco products to be legally marketed in the United States must receive an authorization, the FDA said, adding that to date, it had authorized only four oral tobacco products.

As of April, the FDA had not authorized any ZYN product for sale in the United States, it said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.